USA – Abbott, a global healthcare leader, announced that it has acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive mechanical aspiration thrombectomy system designed to remove peripheral blood clots.
Walk Vascular’s peripheral thrombectomy systems will be incorporated into Abbott’s existing endovascular product portfolio. Financial terms were not disclosed.
“The acquisition of Walk Vascular fits well into our leading vascular device offerings and further drives Abbott’s ability to provide one-of-a-kind endovascular therapy solutions to improve patient care,” said Julie Tyler, Senior Vice President of Abbott’s vascular business.
This transcation is happening at a time when the global vascular devices market is expected to grow at a CAGR of 6.2% from 2020 to reach US$11.13 billion by 2027.
Vascular diseases cause blockage or narrowing of blood vessels in the neck, arms, legs, or abdomen, except in the heart and brain vessels.
This blockage or reduced blood supply in peripheral vessels increases the risk for heart attacks or strokes and, when left untreated, can lead to amputations.
“Walk Vascular’s technology provides physicians with tools to efficiently remove dangerous clots from blood vessels to improve patient care.”
The increasing prevalence of peripheral vascular diseases associated with obesity, diabetes, and hypertension; growing geriatric population; increasing demand for minimally invasive treatment options; and increasing prevalence of disease-causing lifestyles are the major factors driving the growth of this market.
Walk Vascular’s JETi Peripheral Thrombectomy System and next-generation JETi AIO (All In One) Peripheral Thrombectomy System are unique aspiration systems for the removal of intravascular clots, known as thrombus, that can reduce blood flow and lead to serious complications for patients.
The innovative JETi systems are designed to break-up and remove clots from the peripheral vascular system while reducing the risk of dislodged clots.
The systems are backed by real-world clinical experiences, and Walk is currently enrolling up to 250 patients in the United States and Europe in the JETi Registry.
Both the JETi Peripheral Thrombectomy Systems have received 510(k) clearance from the US Food and Drug Administration (FDA) for the aspiration and breaking up of soft emboli and thrombus from the peripheral vasculature, as well as CE Mark in Europe and approvals in other countries.